Move Toward Better Communication and Collaboration Among Patients, Payers, and Product Developers

Move Toward Better Communication and Collaboration Among Patients, Payers, and Product Developers Share   DIA and the Brookings Institution are collaborating to strengthen communication between health care stakeholder communities. A Model of Patient, Payer, and Product Developer Collaboration to Support Innovating for Value will focus on highlighting the perspectives and outcomes most relevant to patient communities, reimbursement requirements and innovative payment models of most interest for payer groups, and how both can help inform product developers as they drive toward novel value-based innovation. By exploring these issues and setting an actionable agenda for improving communication moving forward, this conference will be an important step toward ensuring that patients, payers, and product developers are each contributing to the creation of cost-effective, quality-producing therapies. DIA Members Save $100. Register by October 9!    Overview | Register Today Session Topics:      • Aligning Perspectives on Value and Outcomes      • Identifying Stakeholder Needs and Challenges to Strategic Communication      • Exploring Opportunities for Efficient Engagement Throughout Discovery,        Clinical Development, Regulatory Review, and Product Use      • Case Studies and Current Initiatives      • Next Steps: Charting a Course Forward      • And More Keynote Speaker:      • James Heywood, Co-Founder, Chairman, PatientsLikeMe Confirmed Speakers:      • Anne C. Beal, MD, MPH, Chief Operating Officer, Patient-Centered Outcomes Research Institute      • Marc M. Boutin, JD, Executive Vice President and Chief Operating Officer, National Health Council      • Shari M. Ling, MD, Deputy Chief Medical Officer, Centers for Medicare & Medicaid Services        Center for Clinical Standards & Quality      • Sean R. Tunis, MD, MSc, President and CEO, Center for Medical Technology Policy      • Rhonda M. Medows, MD, FAAFP, Executive Vice President & Chief Medical Officer        UnitedHealthcare      • Tehseen Salimi, MD, Vice President of Global Evidence and Value Development, Sanofi Aventis      • Frances M. Visco, President, National Breast Cancer Coalition      • Reed V. Tuckson, MD, FACP, Managing Director, Tuckson Health Connections, LLC Who Should Attend?      • Patient groups interested in strengthening patient involvement in medical product development      • Payer groups involved in reimbursement for innovative new products      • Product developers considering the role of external stakeholders in the creation of cost-effective,        quality producing medical products      • Regulators, providers, and academic researchers pursuing cross-sector collaboration to        improve health care stakeholder communication Co-sponsored by:             More Exciting Offerings: US Conference on Rare Diseases & Orphan Products: The New Era in Health Care October 7-9 | North Bethesda, MD Co-sponsored with National Organization for Rare Disorders The annual conference where all stakeholders in the rare disease/orphan product community convene to focus on rare diseases and orphan product research, development, and access. Search the Online Program. Beginning with the End in Mind – Study Endpoints: Targeting Patient-Centered Outcomes October 21-23 | North Bethesda, MD | Register by September 30 and Save up to $200! Gain insight into the tradeoffs and various stakeholder perspectives for developing a study endpoint measurement strategy, including detailed and practical tips for ensuring that measurement tools are adequate to support the targeted objectives with a focus on establishing instrument content validity for the specified clinical trial context of use. Benefit-Risk Assessment from Inception to Maturation: Aligning Regulatory and Industry Goals February 10-14 | Bethesda, MD Join FDA, EMA, Health Canada, and other regulatory agencies, patient, industry and academic representatives to discuss the progress and application of Benefit-risk assessment throughout the development and post-approval life cycle.

Email Preferences    |    My DIA    |    Forward to a Friend    |

Sign up for DIA's Global SmartBrief eNews for the latest in drug development innovations worldwide.